ArticleFrontiers in bioengineering and biotechnology2022
Engineered
Article in Frontiers in bioengineering and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 54 citations in OpenAlex.
- Tailoring Corynebacterium glutamicum for Sustainable Biomanufacturing: From Traditional to Cutting-Edge Technologies.Molecular biotechnology · 2026Review
- 2-Hydroxy-4-Methoxybenzaldehyde (2H4MB): Integrating Cell Culture, Metabolic Engineering, and Intelligent Genome Editing.International journal of molecular sciences · 2026Review
- Production of the Antimicrobial Roseoflavin With Genetically Engineered Corynebacterium glutamicum.Microbial biotechnology · 2025Article
- Metabolic Engineering ofJournal of microbiology and biotechnology · 2025Article
- Two routes for tyrosol production by metabolic engineering of Corynebacterium glutamicum.Biotechnology for biofuels and bioproducts · 2025Article
- Genetic Engineering Approaches for the Microbial Production of Vanillin.Biomolecules · 2024Review
- Fermentative aminopyrrolnitrin production by metabolically engineered Corynebacterium glutamicum.Microbial cell factories · 2024Article
- Vanillin production by Corynebacterium glutamicum using heterologous aromatic carboxylic acid reductases.Biotechnology for biofuels and bioproducts · 2024Article
- Minimal aromatic aldehyde reduction (MARE) yeast platform for engineering vanillin production.Biotechnology for biofuels and bioproducts · 2024Article
- Strategies for improving the production of bio-based vanillin.Microbial cell factories · 2023Review
- Improving growth properties of Corynebacterium glutamicum by implementing an iron-responsive protocatechuate biosynthesis.Microbial biotechnology · 2023Article
- Para‑hydroxybenzaldehyde against transient focal cerebral ischemia in rats via mitochondrial preservation.Experimental and therapeutic medicine · 2022Article
- Comparative Analysis of Catabolic and Anabolic Dehydroshikimate Dehydratases for 3,4-DHBA Production inMicroorganisms · 2022Article
- Article
- Sourcing VanillinFood technology and biotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aromatic aldehydes, including 4-hydroxybenzaldehyde (4-HB aldehyde), protocatechuic (PC) aldehyde, and vanillin, are used as important flavors, fragrances, and pharmaceutical precursors and have several biological and therapeutic effects. Production of aromatic aldehydes in microbial hosts poses a challenge due to its rapid and endogenous reduction to alcohols. To address this hurdle, prospecting of the genome of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.